Osteosarcoma as a secondary malignancy following rhabdomyosarcoma: A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS)
Pediatric Blood & Cancer · 2024-12 · 71 (12)
DOI: 10.1002/pbc.31344 ↗At a glance
Journal article in Pediatric Blood & Cancer, published online on 2024-09-29. Written by Stefan S Bielack and 16 co-authors. Institution: Cooperative Osteosarcoma Study Group, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentrum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Ca…. Major MEDLINE topics: Osteosarcoma, Rhabdomyosarcoma, Neoplasms, Second Primary. Cited 3 times so far (Crossref); 18 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Förderkreis Krebskranke Kinder e.V. Stuttgart.
Abstract (original language)
Background
Osteosarcoma may arise as a secondary malignancy following rhabdomyosarcoma (RMS). We utilized the Cooperative Osteosarcoma Study Group (COSS) database to better understand this association. Patients and methods The COSS database (1980‐05/2023) was searched for patients whose osteosarcoma was preceded by RMS. Eligible patients were analyzed for patient‐, tumor‐, and treatment‐related variables as well as outcomes.
Results
The search revealed 28 eligible osteosarcomas (27 high‐grade central, one periosteal; male:female = 16:12; median age RMS 2.1 [range: 0.9–10.0] years, osteosarcoma 13.5 [7.2–29.0] years). Genetic tumor‐predisposition syndromes were documented in 12 patients. One patient had had a distinct malignancy prior to RMS, two intermittently, seven following osteosarcoma. Local RMS treatment had included radiotherapy in 20/26 cases (two unknown). Secondary osteosarcoma sites were extremity 13, trunk seven, head and neck eight; 15 osteosarcomas were radiation‐associated. There was only one case of primary osteosarcoma metastases. Osteosarcoma treatment included chemotherapy (27), surgery (26), or radiotherapy (2). A macroscopically complete remission of all osteosarcoma sites was achieved in 24 cases. Median follow‐up was 5.8 (range: 0.5–18.4) years after osteosarcoma and 8.1 (1.0–15.4) years for 14 survivors. Actuarial 5‐year overall and event‐free survival were 66% (standard error 9%) and 45% (10%), respectively. Five of 14 deaths were caused by further malignancies.
Conclusion
This series offers a benchmark for patients who develop a secondary osteosarcoma after RMS. Affected patients are generally still in the pediatric age. The results obtained strongly argue for genetic predisposition testing in RMS and against therapeutic leniency in comparable situations.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Cooperative Osteosarcoma Study Group, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentrum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.
- Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster, Münster, Germany.
- Abteilung für Kinder-Onkologie, -Hämatologie und Klinische Immunologie, Medizinische Fakultät der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
- Klinik für Tumororthopädie und Sarkomchirurgie, Universitätsklinikum Essen, Essen, Germany.
- St. Anna Kinderspital, Universitätsklinik für Kinder- und Jugendheilkunde der Medizinischen Universität Wien, Vienna, Austria.
- St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.
ORCID profiles: Stefan S Bielack, Vanessa Mettmann, Stefanie Hecker-Nolting, Arndt Borkhardt, Jendrik Hardes, Leo Kager, Thekla von Kalle, Ewa Koscielniak, Christian P Kratz, Thomas Kühne, Michaela Nathrath, Claudia Rossig, Monika Sparber-Sauer, Mathias Werner, Claudia Blattmann
Funding
- Förderkreis Krebskranke Kinder e.V. Stuttgart
Cite
APA
Bielack, S. S., Mettmann, V., Hecker-Nolting, S., Borkhardt, A., Hardes, J., Kager, L., von Kalle, T., Kevric, M., Koscielniak, E., Kratz, C. P., Kühne, T., Nathrath, M., Rossig, C., Sorg, B., Sparber-Sauer, M., Werner, M., & Blattmann, C. (2024). Osteosarcoma as a secondary malignancy following rhabdomyosarcoma: A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS). Pediatric Blood & Cancer, 71(12). https://doi.org/10.1002/pbc.31344
Vancouver
Bielack SS, Mettmann V, Hecker-Nolting S, Borkhardt A, Hardes J, Kager L, et al. Osteosarcoma as a secondary malignancy following rhabdomyosarcoma: A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS). Pediatric Blood & Cancer. 2024;71(12). doi:10.1002/pbc.31344
BibTeX
@article{Bielack2024,
author = {Bielack, Stefan S and Mettmann, Vanessa and Hecker-Nolting, Stefanie and Borkhardt, Arndt and Hardes, Jendrik and Kager, Leo and von Kalle, Thekla and Kevric, Matthias and Koscielniak, Ewa and Kratz, Christian P and Kühne, Thomas and Nathrath, Michaela and Rossig, Claudia and Sorg, Benjamin and Sparber-Sauer, Monika and Werner, Mathias and Blattmann, Claudia},
title = {Osteosarcoma as a secondary malignancy following rhabdomyosarcoma: A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS)},
journal = {Pediatric Blood & Cancer},
year = {2024},
volume = {71},
number = {12},
doi = {10.1002/pbc.31344}
}
EUVIMED